[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627445":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":30,"collaborators":7,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":40,"eligibilityCriteria":41,"healthyVolunteers":36,"sex":42,"minAge":43,"maxAge":7,"enrollmentInfo":44,"targetDuration":7,"studyType":47,"phases":7,"briefSummary":48,"conditions":49,"keywords":7,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},{"fullName":5,"class":6},"University of Rome Tor Vergata","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Vincenzo Formica, Professor","CONTACT","+390620908190","vincenzo.formica@uniroma2.it",[15],{"facility":16,"status":17,"city":18,"state":19,"zip":20,"country":19,"countryCode":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"Tor Vergata University Hospital","RECRUITING","Rome","Italy","00133","IT",{"type":23,"coordinates":24},"Point",[25,26],12.51133,41.89193,{"lat":26,"lon":25},[29],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"type":31,"investigatorFullName":32,"investigatorTitle":33,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Vincenzo Formica","Professor","100627445","impact-of-early-response-to-first-line-anti-pd-1-monotherapy-in-patients-with-recurrent-andor-metastatic-rm-head-and-neck-squamous-cell-carcinoma-assessed-by-18f-fdg-petct-100627445",false,"NCT07448727","Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and\u002For Metastatic (R\u002FM) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET\u002FCT","Prospective Observational Study On The Impact Of Early Response To First-line Anti-PD-1 Therapy In Patients With Recurrent And\u002FOr Metastatic (R\u002FM) Head And Neck Squamous Cell Carcinoma, Assessed By 18F-FDG PET\u002FCT","PEMBRO-PET","Inclusion Criteria:\n\n* Histological diagnosis of recurrent and\u002For metastatic HNSCC, not amenable for curative locoregional treatment (either surgery or radiotherapy), and amenable for first line systemic treatment\n* CPS PD-L1 \\>=1\n\nExclusion Criteria:\n\n* Any controindication to immune checkpoint inhibitors","ALL","18 Years",{"count":45,"type":46},25,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate the role of early response assessment by 18F-FDG PET\u002FCT in patients with recurrent and\u002For metastatic (R\u002FM) head and neck squamous cell carcinoma with PD-L1 CPS \\>1 treated with pembrolizumab monotherapy, in accordance with routine clinical practice.",[50,51],"Head & Neck Cancer","Head & Neck Squamous Cell Carcinoma","2026-02-28",{"date":54,"type":55},"2026-03-04","ACTUAL",{"date":57,"type":55},"2024-11-20",{"date":59,"type":46},"2027-12",{"name":5,"class":6},1]